Avrygen Corporation is a development stage biotechnology company with a proprietary gene therapy technology. Avrygen is developing therapeutic biological drugs for bone and muscle diseases such as osteoarthritis, rheumatoid arthritis, osteoporosis, muscle wasting, and macular degeneration. The company's NanoKorĀ® platform technology is aimed at overcoming many of the shortcomings of current nucleotide delivery formulations.
??